BidaskClub cut shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a buy rating to a hold rating in a report issued on Tuesday, July 11th.

A number of other equities research analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a sell rating to a hold rating in a report on Monday, April 17th. Deutsche Bank AG dropped their price objective on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a buy rating on the stock in a research report on Friday, May 12th. Vetr raised shares of Teva Pharmaceutical Industries Limited from a buy rating to a strong-buy rating and set a $37.48 price objective on the stock in a research report on Tuesday, April 11th. Cowen and Company reissued an outperform rating and issued a $50.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, April 4th. Finally, Citigroup Inc. dropped their price objective on shares of Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a buy rating on the stock in a research report on Tuesday, April 25th. One research analyst has rated the stock with a sell rating, twenty-two have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited has an average rating of Hold and an average target price of $39.81.

Teva Pharmaceutical Industries Limited (TEVA) opened at 20.60 on Tuesday. The stock has a 50 day moving average price of $32.05 and a 200-day moving average price of $32.28. Teva Pharmaceutical Industries Limited has a 12-month low of $20.41 and a 12-month high of $55.45. The company has a market cap of $20.93 billion, a price-to-earnings ratio of 264.10 and a beta of 0.46.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.18% and a negative net margin of 25.18%. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter in the prior year, the company posted $1.25 earnings per share. The business’s revenue was up 12.9% compared to the same quarter last year. On average, analysts predict that Teva Pharmaceutical Industries Limited will post $4.65 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/07/teva-pharmaceutical-industries-limited-nyseteva-downgraded-to-hold-at-bidaskclub-updated-updated-updated.html.

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in Teva Pharmaceutical Industries Limited by 122.4% in the first quarter. Renaissance Technologies LLC now owns 4,817,763 shares of the company’s stock valued at $154,602,000 after buying an additional 2,651,900 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its position in Teva Pharmaceutical Industries Limited by 405,409.9% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,435,505 shares of the company’s stock valued at $46,065,000 after buying an additional 1,435,151 shares during the period. UBS Asset Management Americas Inc. increased its position in Teva Pharmaceutical Industries Limited by 150.7% in the fourth quarter. UBS Asset Management Americas Inc. now owns 2,004,760 shares of the company’s stock valued at $72,672,000 after buying an additional 1,205,253 shares during the period. Sei Investments Co. increased its position in Teva Pharmaceutical Industries Limited by 103.6% in the second quarter. Sei Investments Co. now owns 1,721,466 shares of the company’s stock valued at $57,188,000 after buying an additional 875,789 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company’s stock valued at $165,461,000 after buying an additional 801,106 shares during the period. Hedge funds and other institutional investors own 56.20% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.